Mechanism: the drug is an immunoglobulin G4 monoclonal antibody that binds to/inhibits mannan-binding lectin associated serine protease. Suppression of LP (lectin pathway) activation
Key inclusion criteria:
Age ≥ 18
eGFR ≥ 30
Proteinuria > 1g/24h
Exclusion:
Immunosuppressant/cytotoxic drugs/eculizumab treatment within 8 weeks prior to screening (unless given for indications other than IgAN)
Systemic corticosteroid treatment within 8 weeks prior to screening
